Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250
578 articles with Merck KGaA, Darmstadt, Germany
Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. Wednesday, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.
Biocytogen Pharmaceuticals ( Beijing ) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck KGaA, Darmstadt, Germany to grant them a sole license to evaluate Biocytogen's proprietary antibodies against at least three distinct targets with an option to acquire some of the assets at a later date for therapeutic product development for all uses worldwide.
FREENOME AND MERCK KGAA, DARMSTADT, GERMANY TO PRESENT DATA ON COMBINATION OF MULTIOMICS PROFILING AND COMPUTATIONAL MODELING AT AACR ANNUAL MEETING
Freenome announced its co-authorship of a study with Merck KGaA, Darmstadt Germany, a leading science and technology company.
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced its co-authorship of a study with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to be presented during the American Association for Cancer Research Annual Meeting 2022 from April 8-13, 2022.
MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing Capabilities
MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany a leading science and technology company, announced the acquisition of MAST® platform from Lonza.
Celeris Therapeutics and Boehringer Ingelheim (BI) have announced they are entering into a collaboration to develop next-generation targeted protein degraders.
EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced 13 abstracts from the Company’s multiple sclerosis portfolio will be presented at the 2022 American Academy of Neurology Annual Meeting, being held April 2-7.
New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favorable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression
EMD Serono announced new real-world data from the MSBase Registry demonstrating MAVENCLAD® tablets had more favorable relapse outcomes and longer time to switch to another disease modifying therapy compared to the oral DMTs fingolimod, dimethyl fumarate and teriflunomide in relapsing multiple sclerosis patients.
MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up
MilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash.
European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib).
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility medication packaging, reduced in size for convenience and environmental impact.
Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™
Unlearn®, developer of the Twintelligent RCT™, today announced that the company has entered into a multi-year collaboration with Merck KGaA, Darmstadt, Germany to accelerate late-stage clinical trials with novel trial designs that include Digital Twins.
Merck KGaA, Darmstadt, Germany, Enters into Option Agreement with Quris on its BioAI Platform for Clinical Safety Prediction
Quris, an artificial intelligence innovator disrupting the pharmaceutical arena, announced it has signed an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, allowing Merck KGaA, Darmstadt, Germany to assess Quris’ BioAI safety prediction platform, comparing it to traditional in vitro and in vivo approaches.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Bayer isn't the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
1/21/2022Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.
TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio
TrialSpark announced today the formation of High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA, Darmstadt, Germany.
1/10/2022The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
Definitive Agreement to Acquire Exelead will Strengthen the CDMO Offering for mRNA of the Life Science Business of Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash.
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
F-star Therapeutics, Inc. (NASDAQ: FSTX), today announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration.